EMA Asks Drugmakers to Use eSubmissions for Parallel Distribution Notices

The European Medicines Agency (EMA) is encouraging companies engaged in parallel distribution to notify the agency of their activities electronically rather than in paper format and has released a guideline to assist them. Parallel distribution involves the transfer of branded drugs from one country into a second country without the authorization of the intellectual property owner. Europe has an active market in parallel imports because of the price variations between countries, the result of mandatory pricing schemes.
International Pharmaceutical Regulatory Monitor